Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
CC transcript
Director departure

CASI Pharmaceuticals, Inc (DE) (CASI) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/26/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/27/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/22/2023 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
03/21/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/21/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/21/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
02/14/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 SC 13G/A FEDERATED HERMES, INC. reports a 6.6% stake in CASI PHARMACEUTICALS, INC.
01/31/2023 8-K Acquisition/merger/asset purchase announced
Docs: "THE MERGER"
11/14/2022 8-K Quarterly results
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/23/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET ROCKVILLE, MD. and BEIJING, China CASI Pharmaceuticals, Inc. , a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products , today announced that CASI Biopharmaceuticals Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. , entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP , pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology Co., Ltd. amounting to 12.0098% total Juventas equity to Jiadao Gongcheng for RMB 240.87 million . The Equity Transfer Agreement states there will be two even payment installments from Jiadao Gongcheng: one payment to be made..."
09/09/2022 4 Zukiwski Alexander A (EVP and Chief Medical Officer) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Granted 3,000 options to buy @ $0
09/08/2022 4 Huang James (Director) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Bought 19,162 shares @ $3.8932, valued at $74.6k
Bought 3,111 shares @ $3.9965, valued at $12.4k
Bought 33,300 shares @ $4.2831, valued at $142.6k
09/02/2022 4 Huang James (Director) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Bought 24,975 shares @ $3.745, valued at $93.5k
Bought 11,821 shares @ $3.7229, valued at $44k
Bought 400 shares @ $3.7413, valued at $1.5k
08/26/2022 4 Huang James (Director) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Bought 5,000 shares @ $3.7502, valued at $18.8k
Bought 39,527 shares @ $3.7488, valued at $148.2k
08/23/2022 4 Huang James (Director) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Bought 171,116 shares @ $3.2694, valued at $559.4k
Bought 23,105 shares @ $3.4641, valued at $80k
Bought 40,000 shares @ $3.4998, valued at $140k
08/12/2022 8-K Quarterly results
Docs: "CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS ROCKVILLE, MD. and BEIJING, China CASI Pharmaceuticals, Inc. , a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the second quarter of 2022. Wei-Wu He, Ph.D., CASI’ s Chairman and Chief Executive Officer, commented, “We are pleased to report $8.6 million in EVOMELA ® sales revenue for the second quarter of 2022. This is an increase of 19% compared to the same period last year. Our sales and marketing team is proven to be resilient, rapidly adapting strategies to address COVID-19 related challenges to ensure that our priories remain on track.” Dr. He continued, “Equipped with experience from EVOMELA and the ab..."
08/12/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/21/2022 SC 13D/A He Wei-Wu reports a 19% stake in CASI Pharmaceuticals, Inc.
06/17/2022 4 He Wei-Wu (Chairman and CEO) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Bought 36,058 shares @ $2.97, valued at $107.1k
Bought 2,096 shares @ $3.06, valued at $6.4k
Bought 50,000 shares @ $3.18, valued at $159k
05/26/2022 8-K Quarterly results
05/26/2022 4 Zhou Quan (Director) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Granted 380,645 options to buy @ $0.4664, valued at $177.5k
05/26/2022 4 Huang James (Director) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Granted 397,419 options to buy @ $0.4664, valued at $185.4k
05/26/2022 4 Wu Yue Alexander (Director) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Granted 388,387 options to buy @ $0.4664, valued at $181.1k
05/26/2022 4 Salisbury Franklin Cary jr (Director) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Granted 388,387 options to buy @ $0.4664, valued at $181.1k
05/26/2022 4 SHROTRIYA RAJESH C MD (Director) has filed a Form 4 on CASI Pharmaceuticals, Inc.
Txns: Granted 345,806 options to buy @ $0.4664, valued at $161.3k
05/25/2022 8-K Quarterly results
05/25/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy